Literature DB >> 20078219

Nonalcoholic fatty liver disease: pathology and pathogenesis.

Dina G Tiniakos1, Miriam B Vos, Elizabeth M Brunt.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is recognized as the leading cause of chronic liver disease in adults and children. NAFLD encompasses a spectrum of liver injuries ranging from steatosis to steatohepatitis with or without fibrosis. Fibrosis may progress to cirrhosis and complications including hepatocellular carcinoma. Histologic findings represent the complexity of pathophysiology. NAFLD is closely associated with obesity and is most closely linked with insulin resistance; the current Western diet, high in saturated fats and fructose, plays a significant role. There are several mechanisms by which excess triglycerides are acquired and accumulate in hepatocytes. Formation of steatotic droplets may be disordered in NAFLD. Visceral adipose tissue dysfunction in obesity and insulin resistance results in aberrant cytokine expression; many cytokines have a role in liver injury in NAFLD. Cellular stress and immune reactions, as well as the endocannabinoid system, have been implicated in animal models and in some human studies.

Entities:  

Mesh:

Year:  2010        PMID: 20078219     DOI: 10.1146/annurev-pathol-121808-102132

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  315 in total

1.  Increased expression of zinc finger protein 267 in non-alcoholic fatty liver disease.

Authors:  Bernd Schnabl; Barbara Czech; Daniela Valletta; Thomas S Weiss; Georgi Kirovski; Claus Hellerbrand
Journal:  Int J Clin Exp Pathol       Date:  2011-09-22

Review 2.  Clinical metabolomics paves the way towards future healthcare strategies.

Authors:  Sebastiano Collino; François-Pierre J Martin; Serge Rezzi
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

3.  Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption.

Authors:  Jaimie N Davis; Kim-Anne Lê; Ryan W Walker; Susanna Vikman; Donna Spruijt-Metz; Marc J Weigensberg; Hooman Allayee; Michael I Goran
Journal:  Am J Clin Nutr       Date:  2010-10-20       Impact factor: 7.045

4.  Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice.

Authors:  Ling Yang; Yoon Seok Roh; Jingyi Song; Bi Zhang; Cheng Liu; Rohit Loomba; Ekihiro Seki
Journal:  Hepatology       Date:  2013-12-18       Impact factor: 17.425

5.  Cysteine aggravates palmitate-induced cell death in hepatocytes.

Authors:  Xiaobing Dou; Zhigang Wang; Tong Yao; Zhenyuan Song
Journal:  Life Sci       Date:  2011-10-08       Impact factor: 5.037

6.  Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin.

Authors:  Wenqi Yang; Ling Liu; Yuan Wei; Chunlu Fang; Shujing Liu; Fu Zhou; Yaping Li; Ge Zhao; Ziyi Guo; Yuan Luo; Liangming Li
Journal:  Lab Invest       Date:  2020-12-02       Impact factor: 5.662

7.  Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease.

Authors:  Bryan D Maliken; James E Nelson; Heather M Klintworth; Mary Beauchamp; Matthew M Yeh; Kris V Kowdley
Journal:  Hepatology       Date:  2013-03-14       Impact factor: 17.425

8.  Diffusion analysis with triexponential function in hepatic steatosis.

Authors:  Tatsuya Hayashi; Tosiaki Miyati; Junji Takahashi; Yoshinori Tsuji; Hidesato Suzuki; Naomi Tagaya; Mariko Hiramoto; Kei Fukuzawa; Masakatsu Tano; Satoshi Saitoh
Journal:  Radiol Phys Technol       Date:  2013-10-04

Review 9.  Is hepatic lipogenesis fundamental for NAFLD/NASH? A focus on the nuclear receptor coactivator PGC-1β.

Authors:  Simon Ducheix; Maria Carmela Vegliante; Gaetano Villani; Nicola Napoli; Carlo Sabbà; Antonio Moschetta
Journal:  Cell Mol Life Sci       Date:  2016-08-13       Impact factor: 9.261

10.  5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model.

Authors:  Leyuan Xu; Jin Koung Kim; Qianming Bai; Xin Zhang; Genta Kakiyama; Hae-Ki Min; Arun J Sanyal; William M Pandak; Shunlin Ren
Journal:  Mol Pharmacol       Date:  2012-12-20       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.